Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 9/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944331 | 0.90 | RAB9A (0.49) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL9944354 | 0.87 | MAPT (0.49) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL9944340 | 0.87 | MAPT (0.47) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL9944304 | 0.86 | MAPT (0.50) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL9944220 | 0.85 | MAPT (0.53) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL9944293 | 0.85 | TAS1R3 (0.53) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL1458380 | 0.84 | MEN1 (0.57) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL9944302 | 0.84 | MEN1 (0.49) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL9944320 | 0.83 | TAS1R3 (0.47) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL9944277 | 0.83 | MAPT (0.51) | MEN1KMT2ANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | MEN1 4809/4885KMT2A 1418/4885NPC1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.